Literature DB >> 21637975

Utilization of hypnotic medication in the context of cancer: predictors and frequency of use.

Lucie Casault1, Josée Savard, Hans Ivers, Marie-Hélène Savard, Sébastien Simard.   

Abstract

OBJECTIVE: The present study aims to document the frequency of use of hypnotic medication among a large sample of randomly selected patients having been treated for various types of cancer, as well as to identify the sociodemographic, psychosocial, and medical factors that characterize the users of this type of medication.
METHODS: Five thousand patients who had received treatment for breast, prostate, lung, or colorectal cancer at the L'Hôtel-Dieu de Québec were solicited by mail to take part in this study. Among these patients, 1,984 (39.7%) agreed to complete a battery of questionnaires.
RESULTS: Overall, 22.6% of the patients were currently consuming hypnotic medication. Factors associated with a greater utilization of hypnotic medication were older age, greater difficulties initiating sleep, more stressful life events experienced in the past 6 months, higher levels of anxiety, past or current psychological difficulties, poorer role functioning, less severe urinary symptoms, greater use of opioids, and past or current chemotherapy treatments.
CONCLUSIONS: These results are consistent with those of previous studies conducted in cancer patients in showing high rates of hypnotic medication use. Moreover, this study identified several factors that might help identify persons at risk of using this type of medication and, therefore, to experience the potential negative effects of chronic hypnotics use.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21637975     DOI: 10.1007/s00520-011-1199-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  43 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period.

Authors:  F C Stiefel; A B Kornblith; J C Holland
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

3.  Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use.

Authors:  A Fourrier; L Letenneur; J F Dartigues; N Moore; B Bégaud
Journal:  Eur J Clin Pharmacol       Date:  2001-08       Impact factor: 2.953

4.  Detecting insomnia: comparison of four self-report measures of sleep in a young adult population.

Authors:  S Smith; J Trinder
Journal:  J Sleep Res       Date:  2001-09       Impact factor: 3.981

5.  Sedatives and hypnotics in Stockholm: social factors and kinds of use.

Authors:  G Blennow; A Romelsjö; H Leifman; A Leifman; G Karlsson
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

6.  The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

Authors:  R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

7.  Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer.

Authors:  Colin A Espie; Leanne Fleming; James Cassidy; Leslie Samuel; Lynne M Taylor; Craig A White; Neil J Douglas; Heather M Engleman; Heidi-Louise Kelly; James Paul
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

8.  Sleep disturbance in cancer patients.

Authors:  Judith R Davidson; Alistair W MacLean; Michael D Brundage; Karleen Schulze
Journal:  Soc Sci Med       Date:  2002-05       Impact factor: 4.634

9.  A survey of psychotropic drug prescriptions in an oncology population.

Authors:  L R Derogatis; M Feldstein; G Morrow; A Schmale; M Schmitt; C Gates; B Murawski; J Holland; D Penman; N Melisaratos; A J Enelow; L M Adler
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

10.  Differences in health status between long-term and short-term benzodiazepine users.

Authors:  S M Zandstra; J W Furer; E H van de Lisdonk; J H J Bor; F G Zitman; C van Weel
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

View more
  6 in total

1.  Reply to ‘Evidence for harm, comment on . . .’ by Kripke & Langer.

Authors:  Anton Pottegård; Søren Friis; Morten Andersen; Jesper Hallas
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

2.  Long-Term Effects of Two Formats of Cognitive Behavioral Therapy for Insomnia Comorbid with Breast Cancer.

Authors:  Josée Savard; Hans Ivers; Marie-Hélène Savard; Charles M Morin
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

3.  Medical comorbidity and psychotropic medication fills in older adults with breast or prostate cancer.

Authors:  Salene M W Jones; Dori Rosenberg; Evette Ludman; David Arterburn
Journal:  Support Care Cancer       Date:  2015-02-27       Impact factor: 3.603

4.  Is a video-based cognitive behavioral therapy for insomnia as efficacious as a professionally administered treatment in breast cancer? Results of a randomized controlled trial.

Authors:  Josée Savard; Hans Ivers; Marie-Hélène Savard; Charles M Morin
Journal:  Sleep       Date:  2014-08-01       Impact factor: 5.849

Review 5.  Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Authors:  Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Neldo Antoniello
Journal:  Aging Clin Exp Res       Date:  2013-09-18       Impact factor: 3.636

Review 6.  Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained?

Authors:  Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis
Journal:  Cancer Med       Date:  2014-11-30       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.